GSK’s Tafinlar, Mekinist Prices At Lower End Of Recent Cancer Launches
Executive Summary
GlaxoSmithKline’s pricing of two new melanoma drugs – Tafinlar and Mekinist – is competitive with other melanoma drugs and lower than oncology drugs that have been launched in other indications in recent years. Whether that gives the drugs a commercial edge remains to be seen.